Prostate Cell News Volume 9.12 | Apr 6 2018

TOP STORY

LSD1 Activates a Lethal Prostate Cancer Gene Network Independently of Its Demethylase Function

Researchers showed that lysine-specific demethylase 1 (LSD1) promotes the survival of prostate cancer cells, including those that are castration-resistant, independently of its demethylase function and of the androgen receptor. [Proc Natl Acad Sci USA] Abstract

(Ranked by impact factor of the journal)

Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells

Scientists screened cytotoxic compounds on Pten^−/−;Trp53^−/− fibroblasts and their Pten-WT reference. Highly selective killing of Pten-null cells can be achieved by deguelin, a natural insecticide. In vivo, deguelin suppressed disease in their genetically engineered mouse model for metastatic prostate cancer. [Cell Rep] Abstract | Press Release | Graphical Abstract

SGK1 Inhibition-Induced Autophagy Impairs Prostate Cancer Metastasis by Reversing EMT

Researchers investigated the cellular responses to GSK650394 treatment and serum- and glucocorticoid-induced protein kinase 1 (SGK1) silencing (or overexpression) in human prostate cancer (PCa) cell lines and PC3 xenografts by wound healing assay, migration and invasion assay, western blotting, immunofluorescence and immunohistochemistry. They found that SGK1 expression positively correlates with human PCa progression and metastasis. [J Exp Clin Cancer Res] Full Article

Discrimination Between the Human Prostate Normal and Cancer Cell Exometabolome by GC-MS

Investigators assessed the differences in volatile organic compounds profile in the extracellular medium of four prostate cancer cell lines and one normal prostate cell line at two pH values by gas chromatography-mass spectrometry (GC-MS). [Sci Rep] Full Article

Tumor Necrosis Factor-α Induces Prostate Cancer Cell Migration in Lymphatic Metastasis via CCR7 Upregulation

It has been reported that C‐C chemokine receptor 7 (CCR7), whose ligand is CCL21, is abundantly expressed in lymph node metastasis and promotes cancer progression. Scientists determined whether TNF‐α promotes prostate cancer dissemination from metastatic lymph nodes via activation of the CCL21/CCR7 axis. [Cancer Sci] Full Article

A Novel Mouse Model of Human Prostate Cancer to Study Intraprostatic Tumor Growth and the Development of Lymph Node Metastases

By using different monolayer and 3D spheroid cell cultures in an orthotopic xenograft model, the authors established an innovative, versatile in vivo model of prostate cancer, which enabled the study of both intraprostatic tumor growth as well as metastatic spread to regional lymph nodes. [Prostate] Abstract

Calpain-2 Triggers Prostate Cancer Metastasis via Enhancing CRMP4 Promoter Methylation through NF-κB/DNMT1 Signaling Pathway

Researchers investigated the role of calpain‐2 in collapsing response mediator protein‐4 (CRMP4) promoter hypermethylation and its functional modulation in prostate cancer (PCa) metastasis. [Prostate] Abstract

Hypoxia Leads to Significant Changes in Alternative Splicing and Elevated Expression of CLK Splice Factor Kinases in PC3 Prostate Cancer Cells

Scientists examined the effect of hypoxia on the alternative splicing of cancer associated genes using the prostate cancer cell line PC3 as a model. Secondly, the effect of hypoxia on the expression of several regulators of splicing was examined. [BMC Cancer] Full Article

Enhanced Expression of SRPK2 Contributes to Aggressive Progression and Metastasis in Prostate Cancer

Cell function experiments in prostate cancer cell lines revealed that enhanced serine/arginine-rich protein-specific kinase-2 (SRPK2) expression could promote cell proliferation, migration, invasion and cell cycle progression but suppressed tumor cell apoptosis in vitro. Xenograft experiments showed that SRPK2 promoted tumor growth in vivo. [Biomed Pharmacother] Abstract | Graphical Abstract

Nur77 Suppression Facilitates Androgen Deprivation-Induced Cell Invasion of Prostate Cancer Cells Mediated by TGF-β Signaling

The authors explored the effects of Nur77, an orphan nuclear receptor, on prostate cancer cell invasion following androgen deprivation therapy (ADT). Nur77 over-expression blocked invasion-promoting effect of ADT, which is consistent with the down-regulation of MMP9 and Snail protein expression. [Clin Transl Oncol] Abstract

Delineation of the Androgen-Regulated Signaling Pathways in Prostate Cancer Facilitates the Development of Novel Therapeutic Approaches

Researchers summarize recently described, androgen receptor (AR)-regulated processes that have been demonstrated to promote prostate cancer. By highlighting these signaling events and describing some of the ongoing efforts to pharmacologically modulate these pathways, their goal was to advocate potential new therapeutic targets that would represent an alternative approach for blocking AR actions. [Curr Opin Pharmacol] Abstract

Androgen Receptor Moonlighting in the Prostate Cancer Microenvironment

The authors systematically review the pathological, genomic and biological literature on androgen receptor (AR) actions in various subsets of prostate stromal cells and aim to better understand the consequences of AR signaling in the tumor microenvironment in relation to prostate cancer development and progression. [Endocr Relat Cancer] Abstract | Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

CPRIT Awards UT Southwestern Investigators $16 Million for Cancer Therapy Research

More than a dozen UT Southwestern Simmons Cancer Center researchers received awards from the Cancer Prevention and Research Institute of Texas (CPRIT) for research into breast, prostate, brain, kidney, liver, and pediatric cancers. [The University of Texas Southwestern Medical Center] Press Release

Status Update of the Phase III ARAMIS Clinical Trial with Darolutamide in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

Orion announced that the estimated primary completion date for the joint Phase III clinical trial ARAMIS with darolutamide by Orion and Bayer has been updated. [Orion Corporation] Press Release

Unnecessary Exclusions Shut Patients out of Clinical Trials

The FDA will hold a public meeting in Washington to discuss issues related to clinical trial eligibility criteria. Researchers, study sponsors, patients, and the general public will have an opportunity to share their experiences and tell our regulators why it’s time to revisit the guidelines. [STAT News] Editorial

Why The Ohio State University Decided to Go Public about Misconduct

In an unusual move, The Ohio State University in Columbus released a detailed account of the scientific misbehavior of one of its former faculty members. The 75-page report was damning: It concluded that cancer researcher Ching-Shih Chen—once lauded as an “Innovator of the Year” and the winner of millions of dollars in federal funding—had committed misconduct in eight papers. [ScienceInsider] Editorial

2018 March for Science Will Be Far More than Street Protests

The March for Science has matured. It may even have outgrown its name. [ScienceInsider] Editorial

NEW Goodbye Flat Biology: In Vivo Inspired Cancer Biology and Therapy
September 9-12, 2018
Berlin, Germany

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Scientist – Prostate Oncobiology (Cancer Research UK Manchester Institute)

NEW Postdoctoral Fellows – Molecular and Translational Cancer Biology (Thomas Jefferson University)

NEW Postdoctoral Position – Prostate Cancer (Northwestern University)

Research Scientist – Prostate Cancer (Institute of Oncology Research)

Postdoctoral Position – Drug Development for Cancer (KU Leuven)

Principal Scientist – Translational Research (Medivir AB)

Senior Scientist – Target Discovery and Cancer Biology (Repare Therapeutics)

Postdoctoral Researcher – Cancer Biology (Duke University)

Postdoctoral Associate – Prostate Research (Baylor College of Medicine)

Research Fellowship – Prostate Cancer Pathology (Weill Cornell Medicine)

Postdoctoral Scientist – Cancer Research (Boehringer Ingelheim)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.